DLL3 and large cell neuroendocrine carcinoma: SC-002, another DLL3-directed ADC, showed systemic toxicity and limited efficacy in Phase I clinical trials for the treatment of advanced SCLC and large cell neuroendocrine carcinoma.547 Tarlatamab (AM757) is a half-life extended bispecific T cell engager (BiTE®) targeting DLL3.